FLT3 and neoplasm: Proven effects on tumor cell cycling by FLT3 inhibitors [18,19,20] have led to many clinical trials either as a monotherapy, or as combinatorial therapy with conventional chemotherapy, with early meta-analysis suggesting a statistically significant 17% improvement in survival [21].